✨ MELANOCORTIN BLEND

Melanotan II + PT-141 Blend

This blend pairs Melanotan II (non-selective melanocortin agonist for tanning/pigmentation) with PT-141 (bremelanotide — selective MC3R/MC4R agonist for sexual function). Together they provide complementary melanocortin pathway stimulation for research into photoprotection, pigmentation, and sexual arousal mechanisms.

⚡ QUICKSTART HIGHLIGHTS

VIAL SIZE

20 mg (10mg MT-II + 10mg PT-141)

BAC WATER

2.0 mL

CONCENTRATION

5.0 mg/mL each

1 UNIT =

50 mcg total (25 mcg each)

Dosing & Reconstitution Guide

Reconstitution

Vial	BAC Water	Total Conc.	Each Peptide Conc.	mcg per Unit
20 mg blend	2.0 mL	10 mg/mL total	5.0 mg/mL each	50 mcg total (25 mcg each)

Dosing Protocol

Application	Total Dose	Units	Volume	Notes
Low dose (assess tolerance)	0.25 mg total	5 units	0.05 mL	125 mcg MT-II + 125 mcg PT-141
Standard	0.5 mg total	10 units	0.10 mL	250 mcg each
Higher dose	1.0 mg total	20 units	0.20 mL	500 mcg each — typical per-component dose

Reconstitution Steps

Wipe the vial stopper and BAC water vial with alcohol; let dry.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the blend vial. Do not aim at the powder.
Gently swirl until fully dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within the window specified above.

MT-II component requires UV light exposure within 24 hours of injection to activate melanogenesis. PT-141 component produces sexual arousal effects within 45–60 minutes and lasts 6–12 hours. Administer 45–60 min before desired effect.

How This Works

Melanotan II (MT-II) is a cyclic α-MSH analog that non-selectively activates MC1R (melanogenesis), MC3R (energy/appetite), MC4R (sexual arousal/appetite), and MC5R (exocrine glands). Its key research application is photoprotective tanning via MC1R-stimulated eumelanin synthesis in melanocytes. The cyclic structure provides improved protease resistance versus linear α-MSH.

PT-141 (bremelanotide) is derived from MT-II but with greater selectivity for MC3R and MC4R — the receptors mediating sexual arousal — with lower MC1R activity (less tanning). FDA-approved as Vyleesi for HSDD. Combined, the blend allows simultaneous research into both arms of the melanocortin system at lower per-component doses.

Potential Benefits & Side Effects

Potential Benefits

MT-II: strong melanogenesis via MC1R — deep tan with UV exposure.
PT-141: MC3R/MC4R activation produces central sexual arousal without vascular action.
Lower per-component doses vs standalone — may reduce side effects.
Convenient single vial for dual-mechanism research.
PT-141 FDA approved (Vyleesi) — strongest clinical data of any peptide in this class.

Side Effect Profile

Nausea — MT-II most common adverse effect; dose-dependent.
Flushing, facial redness within 30–60 min.
Spontaneous erections (MT-II — MC4R stimulation).
Darkening of existing moles or nevi — monitor skin.
Elevated blood pressure (PT-141 component — monitor in hypertensive individuals).
UV exposure required for tanning but also increases skin cancer risk — monitor lesions.

Storage Instructions

State	Temperature	Duration
Lyophilized	−20°C (−4°F)	−20°C, up to 24 months
Reconstituted	2–8°C	Up to 28 days

⚠ Research Use Only: PT-141 is FDA-approved (Vyleesi) for HSDD in premenopausal women at 1.75 mg. Research blend doses are lower per component. MT-II is investigational. Monitor skin changes with ongoing use — darkening of moles requires dermatological evaluation.

References

Clayton AH et al. 'Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women' — Obstet Gynecol, 2016 View source ↗

Dorr RT et al. 'Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study' — Life Sci, 1996 View source ↗